UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2014
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
Incorporation)
001-35518 |
|
20-2590184 |
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Other Events
On October 29, 2014, Supernus issued a press release announcing that it expects to report financial results for the quarter ending September 30, 2014 after 5:00 pm ET on November 11, 2014, and will hold a conference call and webcast on November 12, 2014 to review the third quarter 2014 financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit pursuant to Item 2.02 hereof:
Exhibit 99.1 Press Release Dated October 29, 2014 of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SUPERNUS PHARMACEUTICALS, INC. | |
|
| |
DATED: October 30, 2014 |
By: |
/s/ Gregory S. Patrick |
|
Gregory S. Patrick | |
|
Vice-President and Chief Financial Officer |
EXHIBIT INDEX
Number |
|
Description |
|
|
|
|
|
|
|
99.1 |
|
Press Release Dated October 29, 2014 of the Company. |
|
Attached |
Exhibit 99.1
Supernus to Host Third Quarter 2014
Earnings Conference Call
Rockville, MD, October 29, 2014 -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the third quarter 2014 after 5:00 pm ET on Tuesday, November 11, 2014.
Jack Khattar, President and Chief Executive Officer and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter results on Wednesday, November 12, 2014 at 9:00 am ET. Following the presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com. Following the live call, a replay will be available on the Companys website under the Investors section. The webcast will be available on the Companys website for 30 business days following the live call.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
Conference dial-in: |
(877) 288-1043 |
International dial-in: |
(970) 315-0267 |
Conference ID: |
26987068 |
Conference Call Name: |
Supernus Pharmaceuticals 3Q 2014 Earnings Conference Call |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
INVESTOR CONTACT:
COCKRELL GROUP
877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com